- Home
- AXIN vs CTNM Comparison
AXIN vs CTNM Comparison
Compare AXIN & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXIN
- CTNM
- Stock Information
- Founded
- AXIN 2025
- CTNM 2009
- Country
- AXIN United Kingdom
- CTNM United States
- Employees
- AXIN N/A
- CTNM N/A
- Industry
- AXIN
- CTNM
- Sector
- AXIN
- CTNM
- Exchange
- AXIN Nasdaq
- CTNM Nasdaq
- Market Cap
- AXIN 272.1M
- CTNM 248.7M
- IPO Year
- AXIN 2025
- CTNM 2024
- Fundamental
- Price
- AXIN $9.97
- CTNM $12.16
- Analyst Decision
- AXIN
- CTNM Strong Buy
- Analyst Count
- AXIN 0
- CTNM 5
- Target Price
- AXIN N/A
- CTNM $22.20
- AVG Volume (30 Days)
- AXIN 28.8K
- CTNM 194.4K
- Earning Date
- AXIN 01-01-0001
- CTNM 11-05-2025
- Dividend Yield
- AXIN N/A
- CTNM N/A
- EPS Growth
- AXIN N/A
- CTNM N/A
- EPS
- AXIN N/A
- CTNM N/A
- Revenue
- AXIN N/A
- CTNM N/A
- Revenue This Year
- AXIN N/A
- CTNM N/A
- Revenue Next Year
- AXIN N/A
- CTNM N/A
- P/E Ratio
- AXIN N/A
- CTNM N/A
- Revenue Growth
- AXIN N/A
- CTNM N/A
- 52 Week Low
- AXIN $9.93
- CTNM $3.35
- 52 Week High
- AXIN $9.98
- CTNM $20.24
- Technical
- Relative Strength Index (RSI)
- AXIN N/A
- CTNM 56.27
- Support Level
- AXIN N/A
- CTNM $10.65
- Resistance Level
- AXIN N/A
- CTNM $12.14
- Average True Range (ATR)
- AXIN 0.00
- CTNM 0.92
- MACD
- AXIN 0.00
- CTNM -0.21
- Stochastic Oscillator
- AXIN 0.00
- CTNM 34.98
About AXIN Axiom Intelligence Acquisition Corp 1 Class A Ordinary Shares
Axiom Intelligence Acquisition Corp 1 is a blank check company.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.